Search Login Register

sorafenib (BAY 43-9006) Summary

Description: inhibits tumor cell proliferation and angiogenesis by targeting RAF KINASES and VEGF RECEPTORS; multikinase inhibitor that targets serine/threonine and receptor tyrosine kinases to decrease tumor growth and angiogenesis; FDA approved orphan drug indication for hepatocellular carcinoma in 2006

Also Known As: BAY 43-9006; Nexavar; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; BAY 545-9085; BAY-545-9085 Show All >>

Networked: 2977 relevant articles (468 outcomes, 862 trials/studies) for this Drug

Key Diseases for which sorafenib is Relevant

  1. Hepatocellular Carcinoma (Hepatoma) : 173 outcomes 218 studies in 1089 results
  2. Neoplasms (Cancer) : 100 outcomes 229 studies in 1010 results
  3. Renal Cell Carcinoma (Grawitz Tumor) : 72 outcomes 153 studies in 554 results
  4. Neoplasm Metastasis (Metastasis) : 16 outcomes 21 studies in 150 results
  5. Thyroid Neoplasms (Thyroid Cancer) : 15 outcomes 22 studies in 90 results
Show All >>

Drugs Related to sorafenib

  1. sunitinib (Sutent)
  2. Protein-Tyrosine Kinases (Tyrosine Kinase)
  3. Phosphotransferases (Kinase)
  4. bevacizumab
  5. everolimus
  6. temsirolimus
  7. Sirolimus (Rapamycin)
  8. sorafenib (BAY 43-9006)
  9. gemcitabine
  10. Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
Show All >>

Therapies Related to sorafenib

  1. Drug Therapy (Chemotherapy)
  2. Liver Transplantation
  3. Heterologous Transplantation (Xenotransplantation)
  4. Immunotherapy
  5. Transplants (Transplant)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.